*Since the 2003 launch of Somatuline® Autogel® (lanreotide) in Australia, Ipsen has an ongoing commitment to research and development for patients.2-4

What is Somatuline® Autogel® (lanreotide)?

Somatuline® Autogel® is indicated for1:

  • the treatment of acromegaly when the circulating levels of growth hormone and IGF-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory
  • the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours
  • the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally advanced or metastatic disease.
  • The only SSA reimbursed in Australia for non-functioning GEP-NETs5
  • The only SSA registered with the option of injection in clinic or by self/carer1
  • The only long acting SSA delivered in a ready-to-use pre-filled delivery system for deep SC injection1

What is Community Access?

  • What is Community Access?

    The Highly Specialised Drugs (HSD) Community Access program allows healthcare professionals to provide patients with Carcinoid Syndrome or Acromegaly access to Somatuline® Autogel® in their local community. For suitable patients, physicians can prescribe Somatuline® Autogel® using the S100 HSD Community Access code, enabling patients to fill their prescription at their local community pharmacy. Please refer to PBS schedule for full details.6

  • What does Community Access mean for your patients?

    This tailored solution provides flexibility for patients in both access and administration of Somatuline® Autogel®. For some, Community Access may also facilitate self-injection as an appropriate form of administration.1,5-7

  • What does Community Access mean for prescribers?

    HSD Community Access and S100 Public are streamlined authorities which means no phone calls are required to issue scripts, freeing up more time to spend with your patients.1,5,6


  1. Somatuline® Autogel® Approved Product Information.
  2. Adelman DT, et al. Med Devices (Auckl) 2012;5:107.
  3. Data on File, Ipsen.
  4. Australian Government Department of Health, The Pharmaceutical Benefits Scheme (PBS): Schedule of PBS Changes Dec 2018. http://www.pbs.gov.au/publication/schedule/2018/12/2018-12-01-generalsoc.pdf (Accessed 10 July 2019)
  5. Australian Government Department of Health, The Pharmaceutical Benefits Scheme (PBS): Lanreotide.
    http://www.pbs.gov.au/pbs/search?term=lanreotide&searchtype=medicines&analyse=false (Accessed 10 July 2019)
  6. Australian Government Department of Health, The Pharmaceutical Benefits Scheme (PBS): Highly Specialised Drugs
    Program (Community Access). Available at: http://www.pbs.gov.au/browse/section100-ca (Accessed 10 July 2019)
  7. Somatuline® Autogel® Consumer Medicine Information

IGF1: Insulin-like Growth Factor 1; GEPNETS: Gastroenteropancreatic neuroendocrine tumours; SSA: somatostatin analogue; SC: subcutaneous; HSD: Highly Specialised Drugs; PBS: Pharmaceutical Benefits Scheme; ENETS: European Neuroendocrine Tumor Society; NCCN: National Comprehensive Cancer Network; NANETS: North American Neuroendocrine Tumor Society; NETS: Neuroendocrine Tumours; ENSA: Endocrine Nurses’ Society of Australasia.